Revvity Newsroom

Revvity Analyst Ratings

BenzingaJul 8 06:44 ET

Revvity Analyst Ratings

BenzingaJun 28 11:57 ET

Barclays Trims Price Target on Revvity to $115 From $116

MT NewswiresJun 27 08:02 ET

Revvity Analyst Ratings

BenzingaApr 30 11:20 ET

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)

TipRanksApr 30 07:26 ET

Bernstein Adjusts Price Target on Revvity to $123 From $125, Keeps Outperform Rating

MT NewswiresApr 30 06:08 ET

Revvity (RVTY) Receives a Hold From Barclays

TipRanksApr 30 05:50 ET

Nephron Adjusts Revvity's Price Target to $124 From $120

MT NewswiresApr 29 09:55 ET

Barclays Keeps Their Hold Rating on Revvity (RVTY)

TipRanksApr 10 02:55 ET

Raymond James Maintains Outperform on Revvity, Raises Price Target to $127

BenzingaFeb 2 09:01 ET

Revvity Analyst Ratings

BenzingaFeb 2 08:59 ET

Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), Revvity (RVTY) and Becton Dickinson (BDX)

TipRanksFeb 2 08:10 ET

Revvity: A Cautious Hold Amidst Conservative Guidance and Operational Challenges

TipRanksFeb 1 20:06 ET

Buy Rating Affirmed: Revvity's Promising Turnaround and Prudent 2024 Outlook

TipRanksFeb 1 17:05 ET

Revvity: Hold Rating Affirmed Amidst Mixed Financial Performance and Cautious Outlook

TipRanksFeb 1 08:25 ET

BofA Securities Raises Price Target on Revvity to $117 From $104, Maintains Neutral Rating

MT NewswiresJan 29 10:33 ET

The Latest Analyst Ratings For Revvity

BenzingaJan 25 11:00 ET

Revvity Analyst Ratings

BenzingaJan 25 09:53 ET

Revvity Analyst Ratings

BenzingaJan 16 11:32 ET

UBS Downgrades Revvity to Neutral From Buy, Raises Price Target to $125 From $105

MT NewswiresJan 16 10:59 ET